Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | CTSE | P14091 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.37 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22759078 | 0.88 | NR3C1 (0.44) | USP30NR3C1RECQLGPR119KDM4E | |
| SCHEMBL22759226 | 0.88 | USP30 (0.41) | USP30NR3C1RECQLGPR119KDM4E | |
| SCHEMBL22759291 | 0.84 | USP30 (0.40) | USP30NR3C1RECQLGPR119KDM4E | |
| SCHEMBL26199494 | 0.84 | USP30 (0.44) | USP30NR3C1RECQLGPR119KDM4E | |
| SCHEMBL26199407 | 0.84 | USP30 (0.44) | USP30NR3C1RECQLGPR119KDM4E | |
| SCHEMBL25159994 | 0.84 | USP30 (0.44) | USP30NR3C1RECQLGPR119KDM4E | |
| SCHEMBL22759310 | 0.81 | NR3C1 (0.41) | USP30NR3C1RECQLGPR119KDM4E | |
| SCHEMBL22759292 | 0.81 | USP30 (0.39) | USP30GPR119MAPT | |
| SCHEMBL1359746 | 0.80 | USP30 (0.49) | USP30NR3C1RECQLGPR119PIK3CA | |
| SCHEMBL23546390 | 0.80 | USP30 (0.45) | USP30NR3C1GPR119KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-116589467-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116589466-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
| EP-4166556-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| CN-115485278-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021219070-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-11-04 | — | — | WO | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| EP-2155201-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | USP30 1940/4885NR3C1 2963/4885RECQL 339/4885 |
| US-20230167118-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | USP30 186/4885NR3C1 1865/4885RECQL 1938/4885 |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | ATR, CHEK1, CHEK2 | USP30 1816/4885NR3C1 1270/4885RECQL 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.